JP2025502377A - アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用 - Google Patents

アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用 Download PDF

Info

Publication number
JP2025502377A
JP2025502377A JP2024542357A JP2024542357A JP2025502377A JP 2025502377 A JP2025502377 A JP 2025502377A JP 2024542357 A JP2024542357 A JP 2024542357A JP 2024542357 A JP2024542357 A JP 2024542357A JP 2025502377 A JP2025502377 A JP 2025502377A
Authority
JP
Japan
Prior art keywords
pyridin
ethyl
compound
atom
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502377A5 (cg-RX-API-DMAC7.html
Inventor
ボリーズ,セドリック
マシュー,ロイック
ギシュー,ジャン-フランソワ
ジェラン,ミュリエル
ビエシー,オレリアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of JP2025502377A publication Critical patent/JP2025502377A/ja
Publication of JP2025502377A5 publication Critical patent/JP2025502377A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024542357A 2022-01-14 2023-01-13 アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用 Pending JP2025502377A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305031.1 2022-01-14
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors
PCT/EP2023/050692 WO2023135233A1 (en) 2022-01-14 2023-01-13 Azaindole derivatives and their use as erk kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2025502377A true JP2025502377A (ja) 2025-01-24
JP2025502377A5 JP2025502377A5 (cg-RX-API-DMAC7.html) 2026-01-26

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542357A Pending JP2025502377A (ja) 2022-01-14 2023-01-13 アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用

Country Status (16)

Country Link
US (3) US11827637B2 (cg-RX-API-DMAC7.html)
EP (2) EP4212531A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502377A (cg-RX-API-DMAC7.html)
KR (1) KR20240134887A (cg-RX-API-DMAC7.html)
CN (1) CN118541370A (cg-RX-API-DMAC7.html)
AR (1) AR128267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023207276A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002070A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024008809A2 (cg-RX-API-DMAC7.html)
IL (1) IL314199A (cg-RX-API-DMAC7.html)
JO (1) JOP20240157A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008629A (cg-RX-API-DMAC7.html)
TW (1) TW202334147A (cg-RX-API-DMAC7.html)
UA (1) UA130477C2 (cg-RX-API-DMAC7.html)
WO (1) WO2023135233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
WO2025012386A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
AU2024297019A1 (en) * 2023-07-12 2026-01-22 Agv Discovery Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
WO2026064271A1 (en) 2024-09-23 2026-03-26 Fmc Corporation Substituted bicyclic amide derivatives as herbicides
WO2026153964A1 (en) * 2025-01-15 2026-07-23 Ipsen Pharma Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one for use in the treatment of melanoma with braf v600 mutation
WO2026153950A1 (en) 2025-01-15 2026-07-23 Ipsen Pharma Pharmaceutical compositions comprising (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one hydrochloride and at least one carboxylic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
US8697697B2 (en) 2011-01-04 2014-04-15 Kinentia Biosciences Llc Pyrazole derivatives as ERK inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CN113423707A (zh) * 2018-11-16 2021-09-21 加利福尼亚技术学院 Erk抑制剂及其用途
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
TW202334147A (zh) 2023-09-01
WO2023135233A1 (en) 2023-07-20
US11827637B2 (en) 2023-11-28
AR128267A1 (es) 2024-04-10
EP4212531A1 (en) 2023-07-19
CL2024002070A1 (es) 2024-11-29
CN118541370A (zh) 2024-08-23
JOP20240157A1 (ar) 2024-07-14
IL314199A (en) 2024-09-01
CA3242894A1 (en) 2025-02-28
MX2024008629A (es) 2024-08-19
US20230227451A1 (en) 2023-07-20
US12421231B2 (en) 2025-09-23
CO2024008809A2 (es) 2024-08-08
AU2023207276A1 (en) 2024-08-01
US20240308997A1 (en) 2024-09-19
EP4463453A1 (en) 2024-11-20
UA130477C2 (uk) 2026-02-25
KR20240134887A (ko) 2024-09-10
US20260042758A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
CN118541370A (zh) 氮杂吲哚衍生物及其作为erk激酶抑制剂的用途
CN116635371B (zh) 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
WO2022132914A1 (en) Prmts inhibitors
KR102607934B1 (ko) 바닌 억제제로서의 헤테로방향족 화합물
JP2022517723A (ja) Cdk阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
WO2017066014A1 (en) Bruton's tyrosine kinase inhibitors
CN104844566B (zh) 一种新型结构的激酶抑制剂
CN102372717B (zh) 吡咯并嘧啶类化合物及其用途
WO2017049462A1 (zh) 一类新型的flt3激酶抑制剂及其用途
CN110573503B (zh) 作为plk1抑制剂的吡咯衍生物
KR20210034632A (ko) 추가로 치환된 트리아졸로 퀴녹살린 유도체
RU2444515C2 (ru) Производное амида индазолакриловой кислоты
CN109476640B (zh) 双环脯氨酸化合物
JP2022528919A (ja) Malt1阻害剤としての尿素誘導体
CN110804059A (zh) 氨基甲酸酯类化合物、药物组合物及其应用
CN105130992A (zh) 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
CN112341431A (zh) 作为fgfr4抑制剂的杂环化合物
HK40108291A (en) Azaindole derivatives and their use as erk kinase inhibitors
EA050871B1 (ru) Производные азаиндола и их применение в качестве ингибиторов киназы erk
WO2025012383A1 (en) Azaindole derivatives with a cyclo(hetero)aliphatic ring and their use as erk kinase inhibitors
HK40117870A (en) Combination therapies
HK40118806A (en) Combination therapies
WO2025012357A1 (en) Fluorinated azaindole derivatives and their use as erk kinase inhibitors
HK40098242A (en) Combination therapies
HK40100348A (en) Combination therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260107